Emerging strategies for cell and gene therapy of the muscular dystrophies

Lindsey A. Muir; Jeffrey S. Chamberlain

doi:10.1017/S1462399409001100

Emerging strategies for cell and gene therapy of the muscular dystrophies

Published online by Cambridge University Press: 25 June 2009

Lindsey A. Muir and

Jeffrey S. Chamberlain

Show author details

Lindsey A. Muir: Affiliation:
Program in Molecular and Cellular Biology, University of Washington, Seattle, Washington 98195, USA.
Jeffrey S. Chamberlain*: Affiliation:
Department of Neurology, Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, Department of Biochemistry, and Department of Medicine, University of Washington, Seattle, Washington 98195, USA.
*: *Corresponding author: Jeffrey S. Chamberlain, Department of Neurology, University of Washington School of Medicine, HSB Room K233, Box 357720, Seattle, Washington 98195, USA. Tel: +1 206 616 6645; Fax: +1 206 616 8272; E-mail: [email protected]

Article contents

Abstract
References

Get access

Rights & Permissions

Abstract

The muscular dystrophies are a heterogeneous group of over 40 disorders that are characterised by muscle weakness and wasting. The most common are Duchenne muscular dystrophy and Becker muscular dystrophy, which result from mutations within the gene encoding dystrophin; myotonic dystrophy type 1, which results from an expanded trinucleotide repeat in the myotonic dystrophy protein kinase gene; and facioscapulohumeral dystrophy, which is associated with contractions in the subtelomeric region of human chromosome 1. Currently the only treatments involve clinical management of symptoms, although several promising experimental strategies are emerging. These include gene therapy using adeno-associated viral, lentiviral and adenoviral vectors and nonviral vectors, such as plasmid DNA. Exon-skipping and cell-based therapies have also shown promise in the effective treatment and regeneration of dystrophic muscle. The availability of numerous animal models for Duchenne muscular dystrophy has enabled extensive testing of a wide range of therapeutic approaches for this type of disorder. Consequently, we focus here on the therapeutic developments for Duchenne muscular dystrophy as a model of the types of approaches being considered for various types of dystrophy. We discuss the advantages and limitations of each therapeutic strategy, as well as prospects and recent successes in the context of future clinical applications.

Type: Review Article
Information: Expert Reviews in Molecular Medicine , Volume 11 , July 2009 , e18

DOI: https://doi.org/10.1017/S1462399409001100 [Opens in a new window]
Copyright: Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1Emery, A.E.H., eds (2001) The Muscular Dystrophies. Oxford University Press, OxfordCrossRef Google Scholar

2Emery, A.E. and Muntoni, F. (2003) Duchenne Muscular Dystrophy. (3rd, edn), Oxford University Press, OxfordGoogle Scholar

3Wheeler, T.M. et al. (2007) Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. Journal of Clinical Investigation 117, 3952-3957Google Scholar PubMed

4Tawil, R. et al. (1998) Facioscapulohumeral dystrophy: A distinct regional myopathy with a novel molecular pathogenesis. Annals of Neurology 43, 279-282CrossRef Google Scholar PubMed

5Bansal, D. and Campbell, K.P. (2004) Dysferlin and the plasma membrane repair in muscular dystrophy. Trends in Cell Biology 14, 206-213CrossRef Google Scholar PubMed

6Davies, K.E. and Nowak, K.J. (2006) Molecular mechanisms of muscular dystrophies: old and new players. Nature Reviews Molecular Cell Biology 7, 762-773CrossRef Google Scholar PubMed

7Monaco, A.P. et al. (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90-95Google Scholar

8Abmayr, S. and Chamberlain, J.S. (2006) The structure and function of dystrophin. In The Molecular Mechanisms in Muscular Dystrophy (Winder, S.J., eds), pp. 14-34, Landes Biosciences, GeorgetownGoogle Scholar

9Huang, X. et al. (2000) Structure of a WW domain containing fragment of dystrophin in complex with beta-dystroglycan. Nature Structural and Molecular Biology 7, 634-638Google Scholar

10Yoshida, M. and Ozawa, E. (1990) Glycoprotein complex anchoring dystrophin to sarcolemma. Journal of Biochemistry 108, 748-752CrossRef Google Scholar PubMed

11Ervasti, J.M. and Campbell, K.P. (1993) A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. Journal of Cell Biology 122, 809-823CrossRef Google Scholar PubMed

12Petrof, B.J. et al. (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proceedings of the National Academy of Sciences of the United States of America 90, 3710-3714CrossRef Google Scholar

13Turner, P.R. et al. (1988) Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature 335, 735-738CrossRef Google Scholar PubMed

14Batchelor, C.L. and Winder, S.J. (2006) Sparks, signals and shock absorbers: how dystrophin loss causes muscular dystrophy. Trends in Cell Biology 16, 198-205CrossRef Google Scholar PubMed

15Whitehead, N.P. et al. (2006) Streptomycin reduces stretch-induced membrane permeability in muscles from mdx mice. Neuromuscular Disorders 16, 845-854Google Scholar

16Baumbach, L.L. et al. (1989) Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology 39, 465-474Google Scholar

17Ozawa, E. et al. (1998) From dystrophinopathy to sarcoglycanopathy: Evolution of a concept of muscular dystrophy. Muscle & Nerve 21, 421-4383.0.CO;2-B>CrossRef Google Scholar PubMed

18Campbell, K.P. (1995) Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage. Cell 80, 675-679CrossRef Google Scholar PubMed

19Manzur, A. et al. (2008) Glucocorticoid corticosteroids for Duchenne muscular dystrophy Cochrane Database of Systematic Reviews 2008 1 (CD003725), DOI: 10.1002/14651858.CD14003725.pub14651853.CrossRef Google Scholar

20Chamberlain, J.S. and Rando, T.A., eds (2006) Duchenne Muscular Dystrophy: Advances in Therapeutics. Taylor & Francis Group, New YorkCrossRef Google Scholar

21Banks, G.B., Chamberlain, J.S. and Krauss, R.S. (2008) Chapter 9, The value of mammalian models for Duchenne muscular dystrophy in developing therapeutic strategies. Current Topics in Developmental Biology 84, 431-453Google Scholar

22Chamberlain, J. and Caskey, C.T. (1990) Duchenne Muscular Dystrophy. In Current Neurology 10 (Appel, S.H., eds), pp. 65-103, Yearbook Medical Publishers, ChicagoGoogle Scholar

23Chamberlain, J.S. (2002) Gene therapy of muscular dystrophy. Human Molecular Genetics 11, 2355-2362CrossRef Google Scholar PubMed

24England, S.B. (1990) Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180-182CrossRef Google Scholar PubMed

25Matsumura, K. et al. (1994) Immunohistochemical analysis of dystrophin-associated proteins in Becker/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin. Journal of Clinical Investigation 93, 99-105CrossRef Google Scholar PubMed

26Harper, S.Q. et al. (2002) Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nature Medicine 8, 253-261CrossRef Google Scholar PubMed

27Phelps, S.F. et al. (1995) Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Human Molecular Genetics 4, 1251-1258CrossRef Google Scholar PubMed

28Sakamoto, M. (2002) Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochemical and Biophysical Research Communications 293, 1265-1272CrossRef Google Scholar PubMed

29Wang, B., Li, J. and Xiao, X. (2000) Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proceedings of the National Academy of Sciences of the United States of America 97, 13714-13719CrossRef Google Scholar

30Ishikawa-Sakurai, M. et al. (2004) ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to {beta}-dystroglycan. Human Molecular Genetics 13, 693-702Google Scholar

31Huard, J. et al. (1992) Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions. Transplant Proceedings 24, 3049-3051Google Scholar PubMed

32Ohtsuka, Y. et al. (1998) Dystrophin acts as a transplantation rejection antigen indystrophin-deficient mice: implication for gene therapy. Journal of Immunology 160, 4635-4640Google Scholar

33Gilchrist, S.C. et al. (2002) Immune response to full-length dystrophin delivered to DMD muscle by a high-capacity adenoviral vector. Molecular Therapy 6, 359-368Google Scholar

34Wells, D.J., Ferrer, A. and Wells, K.E. (2002) Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophy. Expert Reviews in Molecular Medicine 4, 1-23CrossRef Google Scholar PubMed

35Tinsley, J.M. et al. (1992) Primary structure of dystrophin-related protein. Nature 360, 591-593CrossRef Google Scholar PubMed

36Matsumura, K. et al. (1992) Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature 360, 588-591CrossRef Google Scholar PubMed

37Winder, S.J. et al. (1995) Utrophin actin binding domain: analysis of actin binding and cellular targeting. Journal of Cell Science 108, 63-71CrossRef Google Scholar PubMed

38Nguyen, T.M. (1991) Localization of the DMDL gene-encoded dystrophin-related protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines. Journal of Cell Biology 115, 1695-1700CrossRef Google Scholar PubMed

39Khurana, T.S. et al. (1991) Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromuscular Disorders 1, 185-194CrossRef Google Scholar PubMed

40Mizuno, Y. et al. (1993) Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects. Journal of the Neurological Sciences 119, 43-52Google Scholar

41Weir, A.P., Morgan, J.E. and Davies, K.E. (2004) A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration. Neuromuscular Disorders 14, 19-23CrossRef Google Scholar PubMed

42Deol, J.R. et al. (2007) Successful compensation for dystrophin deficiency by a helper-dependent adenovirus expressing full-length utrophin. Molecular Therapy 15, 1767-1774CrossRef Google Scholar PubMed

43Tinsley, J.M. (1996) Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384, 349-353CrossRef Google Scholar PubMed

44Deconinck, A.E. (1997) Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90, 717-727CrossRef Google Scholar

45Cerletti, M. (2003) Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer. Gene Therapy 10, 750-757CrossRef Google Scholar PubMed

46Odom, G.L. et al. (2008) Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Molecular Therapy 16, 1539-1545CrossRef Google Scholar PubMed

47Atchison, R., Casto, B. and Hammon, W. (1965) Adenovirus-associated defective virus particles. Science 13, 754-756CrossRef Google Scholar

48Muzyczka, N. and Berns, K.I. (2001) Parvoviridae: the viruses and their replication. In Fields Virology (4th edn), (Knipe, D. and Howley, P., eds), pp. 2327-2359, Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar

49Podsakoff, G., Wong, K.K. Jr. and Chatterjee, S. (1994) Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. Journal of Virology 68, 5656-5666CrossRef Google Scholar PubMed

50Gregorevic, P. et al. (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nature Medicine 10, 828-834Google Scholar

51Gao, G. et al. (2004) Clades of adeno-associated viruses are widely disseminated in human tissues. Journal of Virology 78, 6381-6388CrossRef Google Scholar PubMed

52Chao, H. et al. (2000) Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Molecular Therapy 2, 619-623CrossRef Google Scholar PubMed

53Duan, D. et al. (2001) Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. Journal of Virology 75, 7662-7671CrossRef Google Scholar PubMed

54Grimm, D. et al. (2003) Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102, 2412-2419CrossRef Google Scholar PubMed

55Halbert, C.L., Allen, J.M. and Miller, A.D. (2001) Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. Journal of Virology 75, 6615-6624CrossRef Google Scholar PubMed

56Duan, D. et al. (1998) Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. Journal of Virology 72, 8568-8577CrossRef Google Scholar PubMed

57Schnepp, B.C. et al. (2009) Infectious molecular clones of adeno-associated virus isolated directly from human tissues. Journal of Virology 83, 1456-1464Google Scholar

58Chamberlain, J.R. et al. (2004) Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 303, 1198-1201Google Scholar

59Inagaki, K. et al. (2007) DNA palindromes with a modest arm length of greater than or equal to 20 base pairs are a significant target for recombinant adeno-associated virus vector integration in the liver, muscles, and heart in mice. Journal of Virology 81, 11290-11303Google Scholar

60Herzog, R.W. et al. (1999) Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Medicine 5, 56-63Google Scholar

61Manno, C.S. (2003) AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101, 2963-2972CrossRef Google Scholar PubMed

62Yuasa, K. (2002) Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Therapy 9, 1576-1588CrossRef Google Scholar PubMed

63Hartigan-O'Connor, D. et al. (2001) Immune evasion by muscle-specific gene expression in dystrophic muscle. Molecular Therapy 4, 525-533CrossRef Google Scholar PubMed

64Wang, Z. et al. (2007) Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Molecular Therapy 15, 1160-1166CrossRef Google Scholar

65Manno, C.S. et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine 12, 342-347CrossRef Google Scholar PubMed

66Mingozzi, F. and High, K. (2007) Immune responses to AAV in clinical trials. Current Gene Therapy 7, 316-324CrossRef Google Scholar PubMed

67Mingozzi, F. et al. (2007) CD8+ T-cell responses to adeno-associated virus capsid in humans. Nature Medicine 13, 419-422Google Scholar

68Jiang, H. et al. (2006) Effects of transient immunosuppression on adeno-associated virus-mediated liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 108, 3321-3328CrossRef Google Scholar PubMed

69Townsend, D. et al. (2008) Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Molecular Therapy 16, 832-835CrossRef Google Scholar PubMed

70Mah, C. et al. (2005) Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Therapy 12, 1405-1409Google Scholar

71Wang, Z. et al. (2005) Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nature Biotechnology 23, 321-328CrossRef Google Scholar PubMed

72Inagaki, K. et al. (2006) Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Molecular Therapy 14, 45-53CrossRef Google Scholar PubMed

73Yue, Y. et al. (2008) A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Molecular Therapy 16, 1944-1952Google Scholar

74Schultz, B.R. and Chamberlain, J.S. (2008) Recombinant adeno-associated virus transduction and integration. Molecular Therapy 16, 1189-1199Google Scholar

75Banks, G.B. et al. (2007) Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. Human Molecular Genetics 16, 2105-2113Google Scholar

76Wells, K.E. et al. (2003) Relocalization of neuronal nitric oxide synthase (nNOS) as a marker for complete restoration of the dystrophin associated protein complex in skeletal muscle. Neuromuscular Disorders 13, 21-31CrossRef Google Scholar PubMed

77Judge, L.M., Haraguchi, M. and Chamberlain, J.S. (2006) Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. Journal of Cell Science 119, 1537-1546CrossRef Google Scholar PubMed

78Lai, Y. et al. (2009) Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. Journal of Clinical Investigation 119, 624-635Google Scholar

79Thomas, G.D. et al. (1998) Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America 95, 15090-15095CrossRef Google Scholar

80Kobayashi, Y.M. et al. (2008) Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 456, 511-515Google Scholar

81Banks, G.B. et al. (2008) Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. Human Molecular Genetics 17, 3975-3986Google Scholar

82Banks, G.B., Chamberlain, J.S. and Froehner, S.C. (2009) Truncated dystrophins can influence neuromuscular synapse structure. Molecular and Cellular Neuroscience 40, 433-441Google Scholar

83Sun, L., Li, J. and Xiao, X. (2000) Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nature Medicine 6, 599-602CrossRef Google Scholar PubMed

84Yan, Z. et al. (2000) Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proceedings of the National Academy of Sciences of the United States of America 97, 6716-6721Google Scholar

85Nakai, H., Storm, T.A. and Kay, M.A. (2000) Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nature Biotechnology 18, 527-532CrossRef Google Scholar PubMed

86Duan, D., Yue, Y. and Engelhardt, J.F. (2001) Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Molecular Therapy 4, 383-391CrossRef Google Scholar PubMed

87Lai, Y. et al. (2006) Synthetic intron improves transduction efficiency of trans-splicing adeno-associated viral vectors. Human Gene Therapy 17, 1036-1042CrossRef Google Scholar PubMed

88Halbert, C.L., Allen, J.M. and Miller, A.D. (2002) Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nature Biotechnology 20, 697-701CrossRef Google Scholar PubMed

89Ghosh, A. et al. (2007) A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Molecular Therapy 16, 124-130CrossRef Google Scholar

90Li, S. et al. (2005) Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Therapy 12, 1099-1108CrossRef Google Scholar PubMed

91Hacein-Bey-Abina, S. et al. (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New England Journal of Medicine 348, 255-256CrossRef Google Scholar PubMed

92Ciuffi, A. et al. (2006) Integration site selection by HIV-based vectors in dividing and growth-arrested IMR-90 lung fibroblasts. Molecular Therapy 13, 366-373CrossRef Google Scholar PubMed

93Beard, B.C. et al. (2007) Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Human Gene Therapy 18, 423-434CrossRef Google Scholar PubMed

94Barquinero, J., Eixarch, H. and Perez-Melgosa, M.Retroviral vectors: new applications for an old tool. Gene Therapy 11, S3-S9CrossRef Google Scholar

95Kafri, T. et al. (1997) Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nature Genetics 17, 314-317CrossRef Google Scholar PubMed

96Bonci, D. et al. (2003) ‘Advanced’ generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Therapy 10, 630-636CrossRef Google Scholar PubMed

97Naldini, L. et al. (1996) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proceedings of the National Academy of Sciences of the United States of America 93, 11382-11388CrossRef Google Scholar

98Annoni, A. et al. (2007) The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4 + CD25+ regulatory T cells. Blood 110, 1788-1796CrossRef Google Scholar

99Bachrach, E. et al. (2006) Muscle engraftment of myogenic progenitor cells following intraarterial transplantation. Muscle & Nerve 34, 44-52CrossRef Google Scholar PubMed

100Dellavalle, A. et al. (2007) Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nature Cell Biology 9, 255-267Google Scholar

101Kumar-Singh, R. and Chamberlain, J.S. (1996) Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Human Molecular Genetics 5, 913-921Google Scholar

102Clemens, P. et al. (1996) In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Therapy 3, 965-972Google Scholar PubMed

103Chen, H.-H. et al. (1997) Persistence in muscle of an adenoviral vector that lacks all viral genes. Proceedings of the National Academy of Sciences of the United States of America 94, 1645-1650CrossRef Google Scholar

104Hartigan-O'Connor, D. et al. (2002) Generation and growth of adenoviral vectors. Methods in Enzymology 346, 224-246Google Scholar

105DelloRusso, C. et al. (2002) Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proceedings of the National Academy of Sciences of the United States of America 99, 12979-12984CrossRef Google Scholar

106Gilbert, R. et al. (2003) Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Human Molecular Genetics 12, 1287-1299Google Scholar

107Su, L.T. et al. (2005) Uniform scale-independent gene transfer to striated muscle after transvenular extravasation of vector. Circulation 112, 1780-1788Google Scholar

108Gao, G.P., Yang, Y. and Wilson, J.M. (1996) Biology of adenovirus vectors with E1 and E4 deletions for liver- directed gene therapy. Journal of Virology 70, 8934-8943Google Scholar

109Acsadi, G. et al. (1994) A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Human Molecular Genetics 3, 579-584CrossRef Google Scholar PubMed

110Zoltick, P.W. et al. (2001) Biology of E1-deleted adenovirus vectors in nonhuman primate muscle. Journal of Virology 75, 5222-5229Google Scholar

111Muruve, D.A. et al. (1999) Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Human Gene Therapy 10, 965-976CrossRef Google Scholar PubMed

112Brunetti-Pierri, N. et al. (2004) Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Human Gene Therapy 15, 35-46CrossRef Google Scholar PubMed

113Raper, S.E. et al. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular Genetics and Metabolism 80, 148-158Google Scholar

114Morral, N. et al. (1999) Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proceedings of the National Academy of Sciences of the United States of America 96, 12816-12821CrossRef Google Scholar

115Wolff, J. et al. (1990) Direct gene transfer into mouse muscle in vivo. Science 247, 1465-1468CrossRef Google Scholar PubMed

116Zhang, G. et al. (2004) Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of Duchenne muscular dystrophy. Human Gene Therapy 15, 770-782Google Scholar

117Hagstrom, J.E. et al. (2004) A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Molecular Therapy 10, 386-398Google Scholar

118Richard, P. et al. (2005) Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles. Human Gene Therapy 16, 1318-1324CrossRef Google Scholar PubMed

119Chollet, P. et al. (2002) Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. The Journal of Gene Medicine 4, 84-91Google Scholar

120Trubetskoy, V.S. et al. (2003) Recharging cationic DNA complexes with highly charged polyanions for in vitro and in vivo gene delivery. Gene Therapy 10, 261-271CrossRef Google Scholar PubMed

121Romero, N.B. et al. (2004) Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Human Gene Therapy 15, 1065-1076Google Scholar

122Sherratt, T.G. et al. (1993) Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. American Journal of Human Genetics 53, 1007-1015Google Scholar

123Partridge, T. and Lu, Q.-L. (2008) The enigma of the ‘dystrophin revertant’ muscle fibre. In Recent advances in skeletal muscle differentiation (Tsuchida, K. and Takeda, S., eds), pp. 93-107, Research Signpost, TrivandrumGoogle Scholar

124Dominski, Z. and Kole, R. (1993) Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proceedings of the National Academy of Sciences of the United States of America 90, 8673-8677Google Scholar

125Takeshima, Y. et al. (1995) Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. Journal of Clinical Investigation 95, 515-520Google Scholar

126Pramono, Z.A. (1996) Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochemical and Biophysical Research Communications 226, 445-449Google Scholar

127Shibahara, S. et al. (1989) Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives. Nucleic Acids Research 17, 239-252CrossRef Google Scholar PubMed

128Dunckley, M.G. et al. (1998) Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Human Molecular Genetics 7, 1083-1090Google Scholar

129McClorey, G. et al. (2006) Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Therapy 13, 1373-1381CrossRef Google Scholar

130van Deutekom, J.C. (2001) Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Human Molecular Genetics 10, 1547-1554CrossRef Google Scholar PubMed

131Mann, C.J. et al. (2001) Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proceedings of the National Academy of Sciences of the United States of America 98, 42-47Google Scholar

132Summerton, J. and Weller, D. (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense and Nucleic Acid Drug Development 7, 187-195CrossRef Google Scholar PubMed

133Yokota, T. et al. (2009) A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Archives of Neurology 66, 32-38Google Scholar

134Sazani, P. et al. (2002) Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nature Biotechnology 20, 1228-1233CrossRef Google Scholar PubMed

135Lebleu, B. et al. (2008) Cell penetrating peptide conjugates of steric block oligonucleotides. Advanced Drug Delivery Reviews 60, 517-529CrossRef Google Scholar PubMed

136Wu, B. et al. (2009) Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Molecular Therapy 17, 864-871CrossRef Google Scholar PubMed

137Ivanova, G.D. et al. (2008) Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Research 36, 6418-6428Google Scholar

138Alter, J. et al. (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nature Medicine 12, 175-177CrossRef Google Scholar PubMed

139Fletcher, S. et al. (2007) Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Molecular Therapy 15, 1587-1592Google Scholar

140Lu, Q.L. et al. (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proceedings of the National Academy of Sciences of the United States of America 102, 198-203CrossRef Google Scholar

141Jearawiriyapaisarn, N. et al. (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Molecular Therapy 16, 1624-1629Google Scholar

142Wu, B. et al. (2008) Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proceedings of the National Academy of Sciences of the United States of America 105, 14814-14819Google Scholar

143Popplewell, L.J. et al. (2009) Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Molecular Therapy 17, 554-561Google Scholar

144Mitrpant, C. et al. (2009) By-passing the nonsense mutation in the 4 (CV) mouse model of muscular dystrophy by induced exon skipping. The Journal of Gene Medicine 11, 46-56Google Scholar

145De Angelis, F.G. (2002) Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in [delta] 48-50 DMD cells. Proceedings of the National Academy of Sciences of the United States of America 99, 9456-9461Google Scholar

146Goyenvalle, A. et al. (2004) Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping. Science 306, 1796-1799Google Scholar

147Denti, M.A. et al. (2006) Chimeric adeno-associated virus/antisense U1 small nuclear RNA effectively rescues dystrophin synthesis and muscle function by local treatment of mdx mice. Human Gene Therapy 17, 565-574Google Scholar

148Heemskerk, H.A. et al. (2009) In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. The Journal of Gene Medicine 11, 257-266Google Scholar

149Skuk, D. and Tremblay, J.P. (2003) Myoblast transplantation: the current status of a potential therapeutic tool for myopathies. Journal of Muscle Research and Cell Motility 24, 285-300CrossRef Google Scholar PubMed

150Skuk, D. et al. (2007) First test of a “high-density injection” protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscular Disorders 17, 38-46Google Scholar

151Skuk, D. et al. (2007) Ischemic central necrosis in pockets of transplanted myoblasts in nonhuman primates: implications for cell-transplantation strategies. Transplantation 84, 1307-1315Google Scholar

152Montarras, D. et al. (2005) Direct Isolation of Satellite Cells for Skeletal Muscle Regeneration. Science 309, 2064-2067CrossRef Google Scholar PubMed

153Peault, B. et al. (2007) Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Molecular Therapy 15, 867-877Google Scholar

154Webster, C. and Blau, H. (1990) Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somatic Cell and Molecular Genetics 16, 557-565Google Scholar

155Fan, Y. et al. (1996) Rapid death of injected myoblasts in myoblast transfer therapy. Muscle & Nerve 19, 853-860Google Scholar

156Tremblay, J.P. and Skuk, D. (2008) Another new “super muscle stem cell” leaves unaddressed the real problems of cell therapy for Duchenne muscular dystrophy. Molecular Therapy 16, 1907-1909Google Scholar

157Deasy, B.M. et al. (2002) Mechanisms of muscle stem cell expansion with cytokines. Stem Cells 20, 50-60CrossRef Google Scholar PubMed

158Collins, C.A. et al. (2005) Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell 122, 289-301Google Scholar

159Cornelison, D.D.W. (2008) Context matters: In vivo and in vitro influences on muscle satellite cell activity. Journal of Cellular Biochemistry 105, 663-669Google Scholar

160Gussoni, E. et al. (1999) Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401, 390-394Google Scholar

161Lee, J.Y. et al. (2000) Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. Journal of Cell Biology 150, 1085-1100Google Scholar

162Torrente, Y. et al. (2007) Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplantation 16, 563-577Google Scholar

163Ferrari, G. et al. (1998) Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279, 1528-1530Google Scholar

164Dezawa, M. et al. (2005) Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 309, 314-317Google Scholar

165Sampaolesi, M. et al. (2003) Cell therapy of {alpha}-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 301, 487-492Google Scholar

166Sampaolesi, M. et al. (2006) Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444, 574-579Google Scholar

167Barberi, T. et al. (2007) Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nature Medicine 13, 642-648Google Scholar

168Darabi, R. et al. (2008) Functional skeletal muscle regeneration from differentiating embryonic stem cells. Nature Medicine 14, 134-143Google Scholar

169Kimura, E. et al. (2008) Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Human Molecular Genetics 17, 2507-2517CrossRef Google Scholar PubMed

170Takahashi, K. et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872Google Scholar

171Yu, J. et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920Google Scholar

172Rebuzzini, P. et al. (2008) Chromosome number variation in three mouse embryonic stem cell lines during culture. Cytotechnology 58, 17-23Google Scholar

173Catalina, P. et al. (2008) Human ESCs predisposition to karyotypic instability: Is a matter of culture adaptation or differential vulnerability among hESC lines due to inherent properties? Molecular Cancer 7, 76Google Scholar

174Hanna, J. et al. (2007) Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318, 1920-1923Google Scholar

175Dickson, G. et al. (2002) Recombinant micro-genes and dystrophin viral vectors. Neuromuscular Disorders 12, S40-S44Google Scholar

176Goncalves, M.A.F.V. et al. (2008) Targeted chromosomal insertion of large DNA into the human genome by a fiber-modified high-capacity adenovirus-based vector system. PLoS ONE 3, 3084Google Scholar

177Salva, M.Z. et al. (2007) Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Molecular Therapy 15, 320-329Google Scholar

178Zaldumbide, A. and Hoeben, R.C. (2007) How not to be seen: immune-evasion strategies in gene therapy. Gene Therapy 15, 239-246Google Scholar

179van Deutekom, J.C. et al. (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. New England Journal of Medicine 357, 2677-2686Google Scholar

180Newey, S.E. et al. (2000) Alternative splicing of dystrobrevin regulates the stoichiometry of syntrophin binding to the dystrophin protein complex. Current Biology 10, 1295-1298Google Scholar

181Adams, M.E., Mueller, H.A. and Froehner, S.C. (2001) In vivo requirement of the {alpha}-syntrophin PDZ domain for the sarcolemmal localization of nNOS and aquaporin-4. Journal of Cell Biology 155, 113-122Google Scholar

182Gee, S.H. et al. (1998) Interaction of muscle and brain sodium channels with multiple members of the syntrophin family of dystrophin-associated proteins. Journal of Neuroscience 18, 128-137Google Scholar

Article contents

Emerging strategies for cell and gene therapy of the muscular dystrophies

Abstract

Access options

Article purchase

Temporarily unavailable

References

References

Further reading, resources and contacts

This article has been cited by the following publications. This list is generated based on data provided by Crossref.

Article contents

Emerging strategies for cell and gene therapy of the muscular dystrophies

Abstract

Access options

Article purchase

Temporarily unavailable

References

References

Further reading, resources and contacts

Save article to Kindle

Save article to Dropbox

Save article to Google Drive

Reply to: Submit a response

Your details

You have entered the maximum number of contributors

Conflicting interests